|
|
|
|
| LEADER |
00000nam a2200000 a 4500 |
| 001 |
96c413d4-783a-4d87-af7c-888256734e92 |
| 005 |
20240705000000.0 |
| 008 |
020218r20011993mdua b 000 0 eng d |
| 035 |
|
|
|a (OCoLC)49034101
|
| 040 |
|
|
|a COV
|c COV
|d MnU-B
|
| 049 |
|
|
|a UMMA
|
| 090 |
|
|
|a RC377
|b .M52 2001
|
| 245 |
0 |
0 |
|a Multiple sclerosis /
|c Anne H. Cross, guest editor.
|
| 246 |
3 |
0 |
|a 50th anniversary reprint collection, multiple sclerosis
|
| 260 |
|
|
|a Hagerstown, MD :
|b Lippincott Williams & Wilkins,
|c ©2001.
|
| 300 |
|
|
|a 53 pages :
|b illustrations ;
|c 28 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|
| 490 |
1 |
|
|a Neurology ;
|v v. 57, no. 12, suppl. 5
|
| 500 |
|
|
|a Reprints of articles originally published in Neurology from 1993-2000.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
0 |
0 |
|t Landmark papers in multiple sclerosis
|g /
|r Anne H. Cross
|g (2001) --
|t Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
|g /
|r The IFNB Multiple Sclerosis Study Group
|g (1993) --
|t Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
|g /
|r D.W. Paty ... [et al.]
|g (1993) --
|t Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis : results of a phase III multicenter, double-blind, placebo-controlled trial
|g /
|r K.P. Johnson ... [et al.]
|g (1995) --
|t Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
|g /
|r R. A. Rudick ... [et al.]
|g (1997) -- The
|t impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial
|g /
|r J.H. Noseworthy ... [et al.]
|g (1994) -- The
|t 5-year risk of MS after optic neuritis : experience of the Optic Neuritis Treatment Trial
|g /
|r Optic Neuritis Study Group
|g (1997) --
|t Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
|g /
|r K.P. Johnson ... [et al.]
|g (1998).
|
| 650 |
|
0 |
|a Multiple sclerosis
|x Etiiology.
|
| 650 |
|
0 |
|a Multiple sclerosis
|x Chemotherapy.
|
| 650 |
|
2 |
|a Multiple Sclerosis
|x drug therapy
|
| 650 |
|
2 |
|a Multiple Sclerosis
|x etiology
|
| 700 |
1 |
|
|a Cross, Anne H.
|
| 773 |
1 |
8 |
|g no:57
|g iss:11-12+suppl.
|w 9914048710001701
|
| 830 |
|
0 |
|a Neurology ;
|v v. 57, no. 12, suppl. 5.
|
| 999 |
1 |
0 |
|i 96c413d4-783a-4d87-af7c-888256734e92
|l 9952866880001701
|s US-MNU
|m multiple_sclerosis_________________________________________________________1993_______lippia___________________________________________________________________________p
|